The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

Small- and mid-cap biotech looks like one of healthcare's more asymmetric setups after a four-year bear market, as AI speeds drug discovery and Big Pharma faces a patent cliff. Over $300B of pharma revenue goes off patent in the next few years, M&A is already ramping hard as pharma hunts for assets, and many small and mid-cap names still trade at reasonable valuations, making them potential takeover targets. x.com 

Biotech looks vulnerable relative to pharma if higher oil keeps rates higher for longer. United Airlines' CEO plans around $175 oil by the end of next year, Qatar expects five years to restore lost gas capacity, and one-year forward oil near $76 versus $98 spot may underprice the long recovery. Biotech is highly rate-sensitive and pharma much less so, yet pharma fell twice as much this month; that could reverse, with biotech hit as a risk asset while pharma falls less or even rises. x.com 

Biotech's usual Q4 strength ahead of JPM season makes aggressive rallies in smaller names highly likely. ARKG is starting to break out, and PDS Biotechnology is showing multiple buy signals. If ARKG keeps running as expected, Nautilus Biotechnology, PDS Biotechnology and Quantum-Si could reasonably rally toward about $10 soon; broken chart structures would invalidate that view. x.com  x.com 

Biotech is drawing some of the largest long-term buying ever into the SPDR S&P Biotech ETF as it pushes toward its 2021 all-time high. Heavy buy volume, including another historic dollar-volume spike last week, matters more than short-term uncertainty, and the selling has been inefficient. If price loses $154.20 again, the bear case comes back into play. x.com 

Fintech is investing while biotech is gambling: roughly 90% of biotechs fail versus 10% of fintechs. Most fintechs are growing 25-30% or more yet trade at record-low valuations, while biotech is already up 90% and in a bubble driven by buyout mania. x.com 

Significant discounts to broader pharmaceutical industry valuations on projected 2031 earnings make some high-quality mid-cap biotech stocks attractive. Many have cleared Phase 3 trials or reached more advanced stages, and some may reach profitability without more capital, an advantage if financing tightens. Selling these stocks to chase speculative biotech or large pharma at historically elevated multiples makes little sense. x.com 

Biotech looks like a sector that wants to trend higher. Biotech M&A drove a heavy-volume weekly move to the top of a multi-month range; it just needs some help from the macro environment. x.com 

Biotech looks weak as rates finally appear to be weighing on the sector. The biotech ETF closed red well below its 50-day moving average, its 100-day is below its 150-day, and the chart is messy. x.com 

Biotech stocks can keep breaking out because AI is set to create a biotech boom and rate cuts look likely. Fears of higher rates came when oil was $112; with oil now under $70, rates should come down. x.com